Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office
Patent JP6692856 upheld for second time in response to invalidation challenge.
Stay updated with breaking news from Crispr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patent JP6692856 upheld for second time in response to invalidation challenge.
CAR T therapy safety falls into question as the FDA investigates reports of rare T cell lymphoma after treatment. This concern could be resolved with CRISPR technology.
The approval of the first Crispr-based therapy is just the beginning. Getting it to patients is the next hurdle.
The single-dose therapy involves treating and editing patient stem cells ex vivo, then reinfusing them.
Patients with severe sickle cell disease could soon be freed from vaso-occlusive crises after receiving an infusion of exa-cel, the first gene-editing therapy to use CRISPR technology.